Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
NCT00612716
Completed
RATIONALE: Giving chemotherapy, such as cyclophosphamide and busulfan, and total-body irradiation before a donor stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells from bone marrow or umbilical cord blood may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune... Read More
Gender:
ALL
Ages:
55 years and below
Trial Updated:
11/12/2020
Locations: Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
Conditions: Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Register for Updates
Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant
NCT00305682
Completed
RATIONALE: Drugs used in chemotherapy, such as fludarabine and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill cancer cells. An umbilical cord blood transplant may be able to replace blood-forming cells that were destroyed by chemotherapy and radiation therapy. Sometimes the transplanted cells from a donor can make an immune response against the body's nor... Read More
Gender:
ALL
Ages:
75 years and below
Trial Updated:
10/30/2020
Locations: Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota
Conditions: Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes
Register for Updates
Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies
NCT00741455
Completed
The purpose of this study is to determine disease-free survival, overall survival, time to progression, regimen-related toxicity and/or treatment-related mortality in patients with hematologic malignancies treated with non-myeloablative chemotherapy followed by allogeneic stem cell transplant.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
10/30/2020
Locations: Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
Conditions: Hematologic Malignancies
Register for Updates
CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors
NCT02757391
Terminated
This phase I pilot trial studies the side effects of cluster of differentiation 8 (CD8)+ T cells in treating patients with gastrointestinal tumors that have spread to other places in the body. Tumor cells and blood are used to help create an adoptive T cell therapy, such as CD8+ T cell therapy, that is individually designed for a patient and may help doctors learn more about genetic changes in the tumor. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/28/2020
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Colorectal Adenocarcinoma, Metastatic Cholangiocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Digestive System Carcinoma, Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Pancreatic Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IV Esophageal Cancer AJCC v7, Stage IV Gastric Cancer AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
Register for Updates
Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients
NCT00577993
Completed
The goal of this clinical research study is to compare chemotherapy given with rituximab to chemotherapy followed by rituximab. The safety of both treatment schedules will be studied. Laboratory tests of genetic changes in blood and bone marrow before and during the study will also be monitored.
Gender:
ALL
Ages:
76 years and below
Trial Updated:
10/22/2020
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Lymphoma
Register for Updates
Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma
NCT00058422
Completed
RATIONALE: Monoclonal antibodies such as rituximab and yttrium Y 90 ibritumomab tiuxetan can locate cancer cells and either kill them or deliver radioactive cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining rituximab and combination chemotherapy with yttrium Y 90 ibritumomab tiuxetan may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness o... Read More
Gender:
ALL
Ages:
Between 60 years and 120 years
Trial Updated:
10/19/2020
Locations: Memorial Sloan Kettering Cancer Center, New York, New York +1 locations
Conditions: Lymphoma
Register for Updates
Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation
NCT02750254
Terminated
Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative therapy for patients with hematologic malignancies including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL); however, human leukocyte antigen (HLA)-matched donor availability continues to be a major hurdle. Historically, HLA haploidentical donor hematopoietic cell transplantation (haplo-HCT) was associated with high incidences of graft rejection and excessive n... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/16/2020
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphocytic Leukemia
Register for Updates
Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis
NCT03426969
Completed
This early phase I trial studies the side effects of combination chemotherapy, total body irradiation, and donor blood stem cell transplant in treating patients with primary or secondary myelofibrosis. Drugs used in chemotherapy, such as melphalan, fludarabine phosphate, cyclophosphamide, tacrolimus, mycophenolate mofetil, and filgrastim work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radi... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
10/12/2020
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Primary Myelofibrosis, Secondary Myelofibrosis
Register for Updates
Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma
NCT01675765
Completed
This clinical trial will evaluate the safety and immune response of the sequential administration cancer vaccine CRS-207 (with or without cyclophosphamide) followed by standard of care chemotherapy (pemetrexed and cisplatin). CRS-207 is a weakened (attenuated) form of Listeria monocytogenes that has been genetically-modified to reduce its capacity to cause disease, while maintaining its ability to stimulate potent immune responses. CRS-207 has been engineered to elicit an immune response against... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/28/2020
Locations: University of California at San Francisco, San Francisco, California +4 locations
Conditions: Malignant Pleural Mesothelioma
Register for Updates
Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma
NCT02541565
Completed
This pilot phase I trial studies the side effects of pembrolizumab and combination chemotherapy in treating patients with previously untreated diffuse large B-cell lymphoma or grade 3b follicular lymphoma. Monoclonal antibodies, such as pembrolizumab and rituximab, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone, work in different ways to stop the growth of canc... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/22/2020
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Composite Lymphoma, Grade 3b Follicular Lymphoma, Stage I Diffuse Large B-Cell Lymphoma, Stage I Follicular Lymphoma, Stage II Diffuse Large B-Cell Lymphoma, Stage II Follicular Lymphoma, Stage III Diffuse Large B-Cell Lymphoma, Stage III Follicular Lymphoma, Stage IV Diffuse Large B-Cell Lymphoma, Stage IV Follicular Lymphoma
Register for Updates
Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma
NCT00101010
Completed
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving rituximab together with combination chemotherapy may kill more cancer cells. PURPOSE: This phase II... Read More
Gender:
ALL
Ages:
61 years and above
Trial Updated:
09/22/2020
Locations: Hembree Mercy Cancer Center at St. Edward Mercy Medical Center, Fort Smith, Arkansas +6 locations
Conditions: Lymphoma
Register for Updates
PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer
NCT01697293
Terminated
This phase I/II trial studies the side effects and the best dose of triciribine phosphate when given together with paclitaxel, doxorubicin hydrochloride, and cyclophosphamide and to see how well they work in treating patients with stage IIB-IV breast cancer. Triciribine phosphate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel, doxorubicin hydrochloride, and cyclophosphamide, work in different ways to stop... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/22/2020
Locations: Moffitt Cancer Center, Tampa, Florida +1 locations
Conditions: Breast Adenocarcinoma, Estrogen Receptor Positive, HER2/Neu Negative, Recurrent Breast Carcinoma, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Register for Updates